Daping hospital
Chongqing, China
NCT Number: NCT07065422
Occult pleural dissemination (PD) in non-small cell lung cancer (NSCLC) patients is likely to be missed on computed tomography (CT) scans, associated with poor survival, and generally contraindicated for radical surgery. This study aimed to develop and compare the performance of radiomics-based machine learning (ML), deep learning (DL), and fusion models to preoperatively identify occult PDs in NSCLC patients. Patients from three Chinese high-volume medical centers (2016-2023) were retrospectively collected and divided into training, internal test, and external test cohorts. Ten radiomics-based ML models and eight DL models were trained using CT plain scan images at the maximum cross-sectional areas of the primary tumor. Moreover, another two fusion models (prefusion and postfusion) were developed using feature-based and decision-based methods. The receiver operating characteristic curve (ROC) and area under the curve (AUC) were mainly used to compare the predictive performance of the models.
Looking for future studies?
Notify MeAll sexes
Observational
Chongqing, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: through study completion, an average of 6 months.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Other
Comparing Radiomics, Deep Learning, and Fusion Models for Predicting Occult Pleural Dissemination in Patients With Non-small Cell Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT05348668
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hefei, Anhui, China
View Trial DetailsNCT04702009
Advanced Lung Carcinoma, Bronchial Neoplasms
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06477055
Bronchial Neoplasms, Carcinoma, Bronchogenic
Changsha, Hunan, China
View Trial Details